Peptides and metabolic health

Incretin peptides - GLP-1 and GIP - regulate insulin release, appetite and gastric emptying. Medicines that act on these pathways have been tested in tens of thousands of people in randomised trials, making metabolic health the one peptide area where the human evidence base is genuinely large.

Incretin peptides such as GLP-1 and GIP have the largest human trial record of any peptide category. What the trials show, and what remains uncertain.

This is where peptide science has produced its clearest, best-documented human results.

Key takeaways

The incretin system

When food reaches the gut, cells release GLP-1 and GIP. These peptides amplify insulin release in response to glucose, suppress glucagon, slow gastric emptying and signal satiety in the brain. Natural GLP-1 is degraded within minutes, which is why the medicines are engineered to resist that breakdown and last for hours or days.

What the trials measured

The programmes behind approved incretin medicines are unusually large for this field, with randomised, placebo-controlled trials reporting glucose control, body weight, and in several cases cardiovascular and kidney outcomes.

The scale is the important part. It is what allows regulators to describe both effect sizes and adverse events with reasonable confidence - a level of certainty that does not exist for any grey-market peptide.

Known adverse effects

Common and documented effects in trials include:

Open questions

What happens over decades of use, how best to preserve muscle during rapid weight loss, what occurs after stopping, and how these medicines behave in populations not well represented in the original trials are all active research questions rather than settled matters.

Frequently asked questions

Why is metabolic peptide evidence so much stronger than other areas?

Because commercial drug development funded very large randomised controlled trials with hard clinical endpoints. Most other peptides have never had anything comparable.

Are compounded GLP-1 products the same as approved ones?

No. Compounded preparations are not FDA-approved products, and regulators have issued warnings about compounded and counterfeit GLP-1 products. Check the current FDA record.

Does weight return after stopping?

Trials that included a withdrawal phase generally observed substantial weight regain after discontinuation, which is one reason these are framed as long-term treatments for a chronic condition.

Related on Beiing

Sources

  1. FDA - Drug Approvals and Databases - U.S. Food and Drug Administration
  2. ClinicalTrials.gov - U.S. National Library of Medicine
  3. PubMed - National Library of Medicine - NIH

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.